ArticleBlood advances2019
Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04716452 (Phase I Study of C6 Ceramide NanoLiposome), which is not on this map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Glucosylceramide synthase is required for C6-ceramide nanoliposome-induced organelle stress and cell death.bioRxiv : the preprint server for biology · 2026Article
- Curcumin as a ceramide metabolism-targeting agent: Molecular mechanisms and therapeutic implications in cancer.Molecular biology reports · 2026Review
- Phosphatidic acid phosphatase LPIN1 in phospholipid metabolism and stemness in hematopoiesis and AML.HemaSphere · 2025Article
- Influences on the Hematopoietic Stem Cell Niche.SciBase hematology & blood disorders · 2024Article
- A phase I study of the ceramide nanoliposome in patients with advanced solid tumors.Cancer chemotherapy and pharmacology · 2024Article
- The Role of Ceramide and Sphingolipid Metabolism in Cancer Therapeutics.Journal of oncology research and therapy · 2024Article
- Therapeutic Potential of Ceramide in Cancer Treatment.Journal of cancer research and oncobiology · 2024Article
- Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy.Scientific reports · 2023Article
- Advances in tumor nanotechnology: theragnostic implications in tumors via targeting regulated cell death.Apoptosis : an international journal on programmed cell death · 2023Review
- Recent advance in phytonanomedicine and mineral nanomedicine delivery system of the treatment for acute myeloid leukemia.Journal of nanobiotechnology · 2023Review
- Plasma lipidome acts as diagnostic marker and predictor for cyclosporin response in patients with aplastic anemia.Clinical and experimental medicine · 2023Article
- Article
- Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies.International journal of molecular sciences · 2022Review
- Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.Blood reviews · 2022Review
- Ceramide: improving Bcl-2 inhibitor therapy.Blood · 2022Article
- Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.Blood · 2022Article
- Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- A nano-enhanced vaccine for metastatic melanoma immunotherapy.Cancer drug resistance (Alhambra, Calif.) · 2022Article
- Cholesterol-associated lysosomal disorder triggers cell death of hematological malignancy: Dynamic analysis on cytotoxic effects of LW-218.Acta pharmaceutica Sinica. B · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 5 institutions in 1 country.
Brian M BarthDepartment of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH.ORCID 0000-0002-3542-1804
Weiyuan WangDepartment of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH.
Paul T ToranDepartment of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH.
Todd E FoxDepartment of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA.
Charyguly AnnageldiyevDivision of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA.
Regina M OndrasikDivision of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA.
Nicole R KeaseyDivision of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA.
Timothy J BrownDivision of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA.ORCID 0000-0002-4843-4639
Viola G DevineDivision of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA.
Emily C SullivanDepartment of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH.
Andrea L CoteDepartment of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH.
Vasiliki PapakotsiDepartment of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH.
Su-Fern TanDivision of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA.
Sriram S ShanmugavelandyDepartment of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA.
Tye G DeeringDepartment of Pharmacology, University of Virginia School of Medicine, Charlottesville, VA.
David B NeedleDepartment of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH.ORCID 0000-0002-7215-5306
Stephan T SternNanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick National Laboratory for Cancer Research, Frederick, MD.
Junjia ZhuDepartment of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA.
Jason LiaoDepartment of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA.
Aaron D VinyHuman Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-7039-0110
David J FeithDivision of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA.
Ross L LevineHuman Oncology and Pathogenesis Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Hong-Gang WangPenn State Hershey Cancer Institute, Hershey, PA.ORCID 0000-0003-0551-0571
Thomas P LoughranDivision of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA.
Arati SharmaDivision of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA.
Mark KesterPenn State Hershey Cancer Institute, Hershey, PA.
David F ClaxtonDivision of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA.ORCID 0000-0001-9209-2405
Pennsylvania State University · USUniversity of New Hampshire · USMemorial Sloan Kettering Cancer Center · USFrederick National Laboratory for Cancer Research · USUniversity of Virginia · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTLR-TRIF mediated induction of GLI3 modulates innate inflammatory responsesP20GM113131 · NIGMS · UNIVERSITY OF NEW HAMPSHIRE · PI DON Michael WOJCHOWSKI · 2017 to 2026
$22.8MTissue Repository and Animal Models CoreP01CA171983 · NCI · UNIVERSITY OF VIRGINIA · PI CLAXTON, DAVID F · 2013 to 2024
$19.9MRegulation of Ceramide-Based Therapeutics in Acute Myeloid LeukemiaK22CA190674 · NCI · UNIVERSITY OF NEW HAMPSHIRE · PI BARTH, BRIAN MICHAEL · 2016 to 2018
$485kNCI NIH HHS K22 CA190674NCI NIH HHS P01 CA171983NCI NIH HHS P30 CA008748NIGMS NIH HHS P20 GM113131
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Agents, PhytogenicCeramidesDrug CarriersDrug Delivery SystemsHumansLeukemia, Myeloid, AcuteLiposomesNanostructuresSphingolipidsTreatment OutcomeVinblastineAntineoplastic Agents, PhytogenicCeramidesDrug CarriersLiposomesSphingolipidsVinblastine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04716452ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.